AARD vs GUTS
AARD: Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing its lead small molecule candidate, ARD-101, for metabolic and rare disease indications. GUTS: Fractyl Health is a clinical-stage medical device and gene therapy company developing the Revita mucosa resurfacing procedure and Rejuva gene therapy platform for type 2 diabetes and metabolic disorders.
Side-by-side fundamentals
| Metric | AARD | GUTS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.48 | $0.76 | |
| Market cap as of 2026-07-23 | $128M | $123M | |
| PEG as of 2026-07-23 | -1.17 | n/a | |
| Net margin as of 2026-07-23 | n/a | -73864.5% | |
| Gross margin as of 2026-07-23 | n/a | +46.2% | |
| Operating margin as of 2026-07-23 | n/a | -100571.0% | |
| ROE as of 2026-07-23 | -61.7% | -852.1% | AARD higher |
| ROA as of 2026-07-23 | -56.3% | -148.1% | AARD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 1.41 | AARD lower |
| Beta as of 2026-07-23 | 4.01 | 1.45 | |
| 1-year return as of 2026-07-22 close | -49.3% | -57.2% | AARD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.